17-11-2026 17:04 via Drugs.com - News for Health Professionals

FDA Approves First Factor XIa Inhibitor for Secondary Stroke Prevention

TUESDAY, Nov. 17, 2026-- The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic...
Read more »

Pharmaceutical Industry news



β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide
American Heart Association, Nov. 6-9
ACR: Brepocitinib Yields Improvements in Cutaneous Sarcoidosis
ACR: Bimekizumab Demonstrates Superior Results to Risankizumab in Psoriatic Arthritis
Greater Estrogen Exposure Linked to Lower Cerebrovascular Pathology
Head-to-Head Comparisons Show Three Antidepressants Have Greater Long-Term Efficacy
Screening, Treating STIs During Pregnancy May Cut Preterm Birth Risk
Paintball-Related Eye Injuries Declined 84.5 Percent From 2005 to 2025
Nearly 1 in 10 U.S. Adults Report Having Chronic Hand Eczema
FDA Approves Rybrevant Faspro for Advanced Head and Neck Squamous Cell Carcinoma
FDA Approves New Drug for Advanced Head and Neck Squamous Cell Carcinoma
Self-Led, Digital Intervention Lowers Anxiety During Pregnancy
PFOA and PFOS Linked to Increased Risk for ER-Negative Breast Cancer
Desktop versie